Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RadEr: WBRT +/- Erlotinib for NSCLC Brain Metastases
NCT01518621Phase 2Terminated
- Sponsor
- Oslo University Hospital
- Start
- May 2012
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Oslo University Hospital. Started May 2012; status: terminated.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01518621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01518621.